July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Imaging biomarkers for AMD and retinal dystrophies for testing new drugs
Author Affiliations & Notes
  • Srinivas R. Sadda
    Doheny Eye Institute, Los Angeles, California, United States
    Ophthalmology , University of California - Los Angeles, Los Angeles, California, United States
  • Footnotes
    Commercial Relationships   Srinivas Sadda, Carl Zeiss Meditec (F), Centervue (C), Heidelberg (C), Optos (C), Optos (F)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 2583. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Srinivas R. Sadda; Imaging biomarkers for AMD and retinal dystrophies for testing new drugs. Invest. Ophthalmol. Vis. Sci. 2018;59(9):2583.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Presentation Description : Retinal imaging technologies have undergone a rapid evolution over the past two decades. The broad clinical availabaility of multimodal imaging technique has created opportunities for the development of new biomarkers which can be used to more precisely diagnose, risk stratify, stage, and monitor the progression of AMD and various retinal dystrophies. For example, various OCT features including drusen volume, subretinal drusenoid deposits, hyporeflective drusen, and intraretinal hyper-reflective features have been idenfitifed as risk factors for development of advanced AMD. Non-exudative neovascular lesions identified by OCT angiography have been shown to predict the development of future exudative complications. Alterations in the choricapillaris on OCT-A have been identified in early and intermediate AMD eyes. These characteristics may be usfeul for selecting the optimal patients for enrollment in future trials. In addition, OCT-based criteria for the recognition of macular atrophy have been defined, which may allow for more precise monitoring of disease progression and assessment of therapeutic response. Moreover, criteria for earlier or incomplete stages of atrophy have been defined which may facilitate the development of early intervention trials. Finally, for inherited retinal diseases the concepts of ellipsoid zone (EZ) width/area and EZ defect area have been introduced, and may prove to be reliable outcome measures for therapeutic trials.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.